Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages 310-313

  Schmidt, Paul J ^a   Racie, Tim ^b   Westerman, Mark ^c   Fitzgerald, Kevin ^b   Butler, James S ^b   Fleming, Mark D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c Intrinsic Lifesciences Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; ERYTHROPOIETIN; HEPCIDIN; SERINE PROTEASE TMPRSS6; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DRUG CARRIER; IRON; IRON CHELATING AGENT; MATRIPTASE 2; MEMBRANE PROTEIN; NANOPARTICLE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; CELL VOLUME; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; ERYTHROPOIESIS; IRON BLOOD LEVEL; IRON CHELATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON RESTRICTION; IRON STORAGE; IRON THERAPY; MICROCYTIC ANEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE; SPLENOMEGALY; THALASSEMIA INTERMEDIA; ANIMAL; BETA-THALASSEMIA; BIOSYNTHESIS; BLOOD; CHEMISTRY; DISEASE MODEL; FEMALE; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; RNA INTERFERENCE;

ADMINISTRATION, ORAL; ANIMALS; BETA-THALASSEMIA; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HEPCIDINS; IRON; IRON CHELATING AGENTS; MEMBRANE PROTEINS; MICE; NANOPARTICLES; PYRIDONES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES;

EID: 84925303329     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23934     Document Type: Article

References (18)

1. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005;105:4103-4105.
2. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-588.
3. Yang B, Kirby S, Lewis J, et al. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci USA 1995;92:11608-11612.
4. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007;109:5027-5035.
5. De Franceschi L, Daraio F, Filippini A, et al. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica 2006;91:1336-1342.
6. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004;124:123-124.
7. Weizer-Stern O, Adamsky K, Amariglio N, et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Am J Hematol 2006;81:479-483.
8. Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008;8:502-511.
9. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-571.
10. Finberg KE, Whittlesey RL, Andrews NC. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood 2011;117:4590-4599.
11. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest 2010;120:4466-4477.
12. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012;119:5021-5029.
13. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010;16:177-182.
14. Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013;121:1200-1208.
15. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest 2013;123:1531-1541.
16. Fisher SA, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2013;8:CD004839[WorldC at]
17. Gutschow P, Schmidt PJ, Han H, et al. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: Correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. Haematologica 2014 Nov 25. pii: haematol.2014.116723. [Epub ahead of print], in press. [WorldCat]
18. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: A longitudinal study. Blood 2013;122:124-133.